Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity
Objective: To describe baseline characteristics and treatment patterns in patients with chorea associated with Huntington disease (HD) by severity of chorea. Background: Though multiple treatment…VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS
Objective: Because neuromelanin derives from the oxidation of free cytosolic dopamine, we hypothesized that enhancing dopamine vesicular encapsulation with vesicular monoamine transporter 2 (VMAT2) will…VMAT2 availability in Parkinson’s Disease with Rapid Eye Movement Sleep Behaviour Disorder
Objective: To use [11C]DTBZ PET imaging to explore vesicular monoamine transporter 2 (VMAT2) availability in Parkinson’s disease (PD) with and without rapid eye movement sleep…Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…Cumulative Real-World Experience with Deutetrabenazine for Huntington’s Disease Chorea at a Single Center of Excellence in the US
Objective: To summarize clinical experience and outcomes with deutetrabenazine (DTBZ) as a treatment for Huntington’s disease (HD) chorea from the Huntington’s Disease Society of America…Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…The effects of acute administration of VMAT2 inhibitors on extracellular levels of dopamine, norepinephrine, 5-HT and histamine in the striatum and medial prefrontal cortex
Objective: To evaluate the effects of reversible VMAT2 inhibitors (deutetrabenazine, tetrabenazine and valbenazine) on extracellular levels of monoamines and their acidic metabolites in rat striatum…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…The Impact of Antipsychotic Dose Reduction Within a Medicare Population
Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial
Objective: To evaluate the efficacy of deutetrabenazine (DTBZ) in reducing TD in the most severely impacted patients using data from an ongoing open-label extension (OLE)…